Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gulf General Cooperative Insurance Company SJSC
SAU:8260
|
SA |
|
Henderson Land Development Co Ltd
HKEX:12
|
HK |
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
BE |
|
HEICO Corp
NYSE:HEI
|
US |
Salarius Pharmaceuticals Inc
Other Items
Salarius Pharmaceuticals Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
Other Items
-$200k
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
32%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Salarius Pharmaceuticals Inc
Glance View
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.
See Also
What is Salarius Pharmaceuticals Inc's Other Items?
Other Items
-200k
USD
Based on the financial report for Sep 30, 2025, Salarius Pharmaceuticals Inc's Other Items amounts to -200k USD.
What is Salarius Pharmaceuticals Inc's Other Items growth rate?
Other Items CAGR 10Y
32%
The average annual Other Items growth rates for Salarius Pharmaceuticals Inc have been 49% over the past three years , and 32% over the past ten years .
